autologous-therapy
(2)
Leucid Bio
Leucid Bio is a clinical-stage London biotech developing next-generation CAR-T cell therapies for refractory solid tumors. Spun out of King's College London in 2014 to commercialize two decades of research by Dr John Maher, the company's proprietary Lateral CAR platform redesigns the CAR receptor so its signalling domains sit laterally alongside the cell membrane - mimicking natural immune receptors to boost potency while reducing toxicity. Its lead candidate, LEU011, is an autologous NKG2D-targeting CAR-T therapy now in the Phase I/IIa AERIAL trial for refractory solid tumors.
Mitrix Bio
Mitrix Bio is a Bay Area biotech startup building bioreactor-grown mitochondria - the cell's power plants - packaged into vesicles it calls 'Mitlets' and delivered by injection. Founded by former SLAC accelerator manager Tom Benson, the company treats the slow decline of mitochondria as a root cause of aging and aims to manufacture autologous, young mitochondria at industrial scale so clinicians can regenerate organs, boost immunity and cognition, and extend healthy human lifespan toward 130 years.